CURRICULUM VITAE

Steven D. Targum, M.D.

505 Tremont Street
907
Boston, Massachusetts 02116
617-357-7474 (x207) (office phone)
617-824-0800 (cell)
email: sdtargum@yahoo.com

Education:

1965 - 1969	Colgate University, Hamilton, NY B.A. magna cum laude with honors in biology
1969 - 1973	Mount Sinai School of Medicine, New York, NY Doctor of Medicine
1973 - 1974	Mount Sinai School of Medicine, New York, NY Residency in Obstetrics-Gynecology
1974 - 1976	Rutgers Institute of Mental Health Science, Piscataway, NJ Residency in Psychiatry
1976 - 1978	National Institute of Mental Health, Bethesda, MD Clinical Associate, Biological Psychiatry and Psychogenetics

Academic Affiliations:

2006 - present	Consultant in Psychiatry Massachusetts General Hospital, Boston, MA
1989 - 1998	Professor of Psychiatry Allegheny University of the Health Sciences, Philadelphia, PA (formerly Hahnemann University School of Medicine)
1989 - 1995	Chairman, Department of Psychiatry Crozer-Chester Medical Center, Upland, PA
1989 - 1995	Vice Chairman, Department of Mental Health Sciences Hahnemann University School of Medicine, Philadelphia, PA
1983 - 1989	Clinical Associate Professor of Psychiatry University of South Florida School of Medicine, Tampa, FL

1979 - 1983	Clinical Assistant Professor of Psychiatry Georgetown University School of Medicine, Washington, D.C.

Professional Experience

2009- present	Founder and Scientific Director Clintara LLC (Boston, Massachusetts)
2009-present	Chief Medical Officer Methylation Sciences Inc. (Vancouver, British Columbia)
2007-present	Chief Medical Advisor Prana Biotechnology Ltd. (Melbourne, Australia)
2007- 2009	Director of Strategic Development Clinical Trials Network Institute Massachusetts General Hospital, Department of Psychiatry (Boston, Massachusetts)
2006- 2009	Chief Medical Officer BrainCells Inc. (San Diego, California)
2005- 2010	Executive-in-Residence Oxford BioScience Partners (Boston, Massachusetts)
2004- 2006	Principal Scientific Advisor United Biosource Corporation (Wayne, Pennsylvania)
2001- 2004	Founder and Chief Scientific Officer Pharmastar LLC (Wayne, Pennsylvania)
1996 – 2001	Vice President of Medical Affairs and CNS Venture Head ICSL, Clinical Studies Ltd
1995 - 1998	Director of Research, Department of Psychiatry Crozer-Chester Medical Center, Upland, PA
1994 - 1996	Founder and Chief Executive Officer Delaware Valley Clinical Studies Center, Philadelphia, PA
1994 – 1996	Medical Director Philadelphia Medical Institute and Memory Institute, Philadelphia, PA

1989 - 1993	Special Reviewer National Institutes of Mental Health, Bethesda, MD
1983 - 1989	Medical Director Sarasota Palms Hospital, Sarasota, Florida
1978 - 1983	Director of Research and Evaluation The Psychiatric Institute of Washington, DC
1978 - 1980	Director, Psychiatric Intensive Care Unit The Psychiatric Institute of Washington
1980 - 1983	Director, National Capital Sleep Centers, Inc. Bethesda, MD
1978 - 1983	Guest Worker, Section on Psychogenetics National Institute of Mental Health, Bethesda, MD

Fellowships:

1968 & 1969	Downstate Medical Center, Brooklyn, NY Department of Anatomy for Research in Genetics
1970	Mt. Sinai Hospital, New York, NY Department of Psychiatry, USPHS
1971	Mt. Sinai Hospital, New York, NY Department of Community Medicine, USPHS
1973	USPHS-AAMC Fellowship in Belgrade, Yugoslavia
1988	Elected to Fellowship, American Psychiatric Association

Professional Memberships/Organizations:

American Psychiatric Association
Society of Biological Psychiatry
International Society for Clinical Drug Development

Licenses:

Active

1989	Pennsylvania, 44778E

Inactive

1974	New Jersey MA29042
1976	Maryland
1978	District of Columbia
1983	Florida

Board Certifications:

1974	National Board of Medical Examiners
1978	American Board of Psychiatry and Neurology

Honors/Awards:

Phi Beta Kappa, Elected to Membership, 1969
Nathaniel Stanton Fellowship Award, Colgate University, 1969
Lange Medical Award, Mount Sinai School of Medicine, 1973
A.E. Bennett Award, Honorable Mention, Society of Biological Psychiatry, 1983
Presidential Award for Research in Psychiatry, National Association of Private Psychiatric Hospitals, 1985

Fellowship, American Psychiatric Association, 1988

Research Experience:

Depression Studies

Double-blind Evaluation of Oxaprotiline versus Imipramine versus Placebo in Patients with Major Depressive Disorder Evaluation of T-cell Function in Patients with Major Depression

A Double-Blind, Parallel Comparison of Sertraline, Imipramine and Placebo in Inpatients with Major Depression or Bipolar Disorder

A Multicenter, Double-blind Trial of Nefazodone and Placebo in the Treatment of Depressed Inpatients

An Open Multicenter Trial of Nefazodone in the Treatment of Patients with Mood Disorders

A Double-Blind Study of Nefazodone and Sertraline in Highly Anxious Out-patients with Major Depression

A Phase II, Double-Blind Study of 3 Different Doses of Roxindole vs Placebo in Outpatients Suffering from Depression

Double-Blind Trial Comparing Nefazodone to Fluoxetine in Patients with Activation Side Effects Previously Demonstrated During Treatment with Fluoxetine for Major Depression

A Phase II, Eight Week, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Oral CP-93,393 in Outpatients with Major Depressive Disorder

Six Month, Open-Label Evaluation of the Safety and Efficacy of Venlafaxine Followed by a Randomized, Double-Blind, Placebo-Controlled One Year Evaluation of Venlafaxine in Prophylactic Treatment of Recurrent Major Depression

A Multicenter, Placebo-Controlled Study of Relapse-Prevention by Long-Term Treatment with High or Low Doses of ORG 4428 in Out-Patients with Recurrent Major Depressive Episode

Fluoxetine Plus Pindolol Versus Fluoxetine Plus Placebo in the Treatment of Major Depression

A Double-Blind, Placebo Controlled Trial to Compare the Clinical Effects of Immediate Release Paroxetine and Modified
Release Paroxetine in the Treatment of Major Depression in Elderly Patients

Double-Blind, Placebo-Controlled Study of Extended Release Venlafaxine and Fluoxetine in Outpatients with Major Depression

Double-Blind, Placebo-Controlled Study of Venlafaxine and Fluoxetine in Inpatients with Major Depression and Melancholia

Fluoxetine Versus Sertraline and Paroxetine in Major Depression: Comparison of Discontinuation-Emergent Signs and Symptoms

Weekly Enteric-Coated Fluoxetine vs Daily Fluoxetine or Placebo in the Continuation Treatment of Major Depressive Disorder

An Eight-Week, Double-Blind, Placebo-Controlled Study of Flibanserin and Paroxetine in Patients with Major Depressive Disorder

Multicenter, Double-blind, Placebo-controlled, Parallel Group Study of the Safety, Tolerability and Efficacy of Three Fixed doses of Fluvoxamine Versus Placebo in Outpatients with Major Depressive Disorder

An Eight-Week, Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled Study of Sertraline in Elderly Outpatients with DSM-IV Major Depression

Olanzapine Added to Mood Stabilizers in the Treatment of Bipolar Disorder

Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of SR 58611A in Outpatients with Major
Depression

Double-Blind, Randomized, Multicenter, Parallel Design Study to Evaluate the efficacy and Safety of Individual Maximum Tolerated Doses of EMD 68 843 in Comparison with Placebo and Fluoxetine in Outpatients with Major Depressive Disorder

Six week, Double-Blind, Placebo-and Fluoxetine-Controlled Multicenter Center to Evaluate the Safety and Efficacy of Oral
CP-122,721 in Outpatients with Major Depressive Disorder

Double-blind, Multicenter, Acute Study of the Antidepressant Efficacy of the Concomitant Use of MK-0869 Plus Paroxetine Hydrochloride Compared to Monotherapy with MK-0869 and Paroxetine Hydrochloride in the Treatment of Outpatients with Major Depressive Disorder

Olanzapine-Divalproex Sodium/Valproic Acid Interaction Trial in Bipolar and Schizoaffective Patients (Phase 1)

Multicenter, Randomized, Double-Blind, Sertraline-Controlled Study of the Efficacy and Safety for Mirtazapine in Subjects with Major Depressive Disorder Who Failed on SSRI Treatment due to Lack of Efficacy

Multicenter, Double-Blind, Flexible Dose Safety Trial Comparing Nefazodone ER to Nefazodone IR in the treatment of Depressed Patients

R-Fluoxetine Versus Placebo in the Treatment of Major Depression

Double Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3 Doses of CP-448,147 and Fluoxetine in Subjects with Major Depressive Disorder

Double Blind Follow-Up Interview Study of Subjects who Participated in the Double Blind Study of Oral CP-122,721 in Outpatients with Major Depressive Disorder

Multicenter, Double-Blind, Placebo and Paroxetine Controlled Randomized Flexible Dose Trial of Nefazodone in the Treatment of Depressed Patients

Double-Blind, Placebo-Controlled Comparative Efficacy Study of Venlafaxine ER and Sertraline in Producing Remission in Outpatients with Major Depressive Disorder

Reboxetine, Placebo, and Paroxetine Comparison in Patients with Major Depressive Disorder

Double-Blind, Placebo and Paroxetine-Controlled Study to Evaluate the Safety and Efficacy of Oral CP-122,721 in Outpatients with Major Depressive Disorder

Double-Blind, Placebo-Controlled, 3-arm Fixed Dose Study of Paroxetine CR Continuous Treatment for Premenstrual Dysphoric Disorder (PMDD)

Duloxetine Once-Daily Dosing Versus Placebo in the Acute Treatment of Major Depression

Double-Blind, Placebo and Paroxetine Controlled, Multicenter, Dose-Ranging Study Evaluating the Efficacy and Safety of SR142801 in Outpatients with Major Depressive Disorder

Seven-Week, Double-Blind, Placebo and Paroxetine-Controlled Study to Evaluate the Safety and Efficacy of Oral CP-122,721 in Outpatients with Major Depressive Disorder and Associated Somatic Symptoms

Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Evaluating Efficacy and Safety of SB-659746-A and Citalopram in Patients with Major Depressive Disorder

Panic-Anxiety Disorder Studies

Double-blind, Randomized Comparison of Clomipramine versus Imipramine versus Placebo in Outpatients with Obsessive-Compulsive Disorder

Short and Long Term Discontinuation of Alprazolam in the Treatment of Panic Disorder with Agoraphobia

A Double-Blind Study of Fluvoxamine in the Treatment of Panic Disorder

Double-Blind, Placebo-controlled, Fixed Dose Study of Ondansetron versus Diazepam in the Treatment of Generalized Anxiety Disorder

Double-blind Study of DN-2327 in Generalized Anxiety Disorder

An Open-Label Study of DN-2327 in Generalized Anxiety Disorder

A Double-Blind Placebo-Controlled Dose Escalation Study of the
Safety and Efficacy of oral Ondansetron in the Treatment of Patients with Panic Disorder (Study 1)

Klonopin Dose Titration Study in Panic Disorder

A Double-Blind, Placebo-Controlled Dose-Escalation Study of
the Safety and Efficacy of Oral Ondansetron in the Treatment of Patients with Panic Disorder (Study 2)

Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Sertindole in the Treatment of Patients with Generalized Anxiety Disorder

A Double-Blind, Placebo Controlled, Flexible Dosing Trial to
Evaluate the Efficacy of Modified Release Paroxetine in the Treatment of Panic Disorder

An Open-label, Long-term, Safety Study of Transdermal Buspirone in the Treatment of Anxious Outpatients

A Double-Blind, Randomized Trial of Three Fixed Doses of Transdermal Buspirone Compared to Placebo in the Treatment of Anxious Outpatients

LY354740 Compared with Placebo and Lorazepam in Outpatients with Generalized Anxiety Disorder

Double-blind Evaluation of Pregabalin in Patients with Generalized Anxiety Disorder

Sustained Efficacy Study of Pregabalin in Patients with Generalized Anxiety Disorder

Open-Label Safety Study of Pregabalin (CI-1008) in Patients with Anxiety Disorders

Six-Month, Double-Blind, Placebo-Controlled Parallel Group Comparison of Venlafaxine Extended Release Capsules and Placebo in Outpatients with Generalized Social Anxiety Disorder

6-week, Double-Blind, BID, Flexible-Dose Study of Pregabalin in Patients with Generalized Anxiety Disorder

Alzheimer's Disease Studies

Efficacy and Safety of Cycloserine in Patients with Alzheimer's Disease

A Controlled Study of Ondansetron in the Treatment of Alzheimer-Type Dementia

A Double-Blind Study of Single Doses of CP-118,954 in Alzheimer's Disease

Clinical Evaluation of Extended-Release Oral Physostigmine in the Treatment of Patients with Dementia of the Alzheimer's Type

An Open Label Extension of Extended-Release Oral Physostigmine Treatment of Patients with Dementia of the Alzheimer's Type

Phase II Open-Label, Multicenter Extension Study of the Safety and Efficacy of CP 118,954 Administered for Twenty-Six Weeks to Subjects with Alzheimer's Disease

Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Three Doses of CP 118,954 Administered for 12 Weeks to Subjects with Alzheimer's Disease

A Prospective, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group Comparison of the Efficacy and Safety of Three Fixed-Doses of SDZ ENA 713 per Day in Patients with Probable Mild to Moderate Alzheimer's Disease

Double-blind Study of the Efficacy and Safety of Nimodipine in Patients with Probable Alzheimer's disease

Open-label Study of the Safety and Efficacy of CP-118,954 in Subjects with Alzheimer's Disease

Clinical Evaluation of the Safety and Efficacy of AF102B vs Placebo in Patients with Dementia of the Alzheimer's Type

Evaluation of LY246708 tartrate (Xanomeline) in Mild to Moderate Alzheimer's disease

Six Month Efficacy and Safety Study of Bisiperdine in Patients with Alzheimer's Disease

Open Label Extension Study of Xanomeline Tartrate in Mild to Moderate Alzheimer's Disease

Preliminary Double-blind, Placebo-controlled Evaluation of Venlafaxine Capsules in Outpatients with Alzheimer's Disease

A 16 Week Open-Label Safety Study of Tacrine with Monitoring of Serum Alanine Aminotransferase at Weeks, 4, 6, 8, 12 and 16

A Placebo-Controlled, Randomized, Double-Blind, Multicenter Study of the Efficacy and Safety of Galantamine in Patients with Probable Alzheimer's Disease of Moderate Severity

Forty-Eight Week Efficacy and Safety Study of Propentofylline in Patients with Alzheimer's Disease (301)

Twenty-Four Week Efficacy and Safety Study of Propentofylline in Patients with Vascular Dementia (302)

Multicenter Study of Tacrine (CI-970) One-a-Day Formulation (Tacrine GITS) with a 12 Month Open-Label Extension in Patients with Dementia of the Alzheimer's Type

An Open-Label, Six-Month Extension Study to Prospectively Evaluate the Long-Term Safety, Tolerability, and Efficacy of SDZ ENA 713 in Outpatients with Probable Alzheimer's Disease

A Prospective, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Groups Comparison of the Efficacy and Safety of low dose SDZ ENA 713 and high dose SDZ ENA 713 in Patients with Mild to Moderate Probable Alzheimer's Disease

Open Label Extension Study to Evaluate Long-Term Administration of SDZ ENA 713 in the Treatment of Patients with Dementia of the Alzheimer's Type

An Open-label Sequential Cohort Study of ENA 713 Designed to Prospectively Evaluate the Tolerability and Safety of Titration Doses at Weekly Increases to a Maximal Daily Dose in Outpatients with Probable Alzheimer's Disease

A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Milameline in Patients with Probable Alzheimer's Disease with Long-Term Open-Label Extension

A 24-Week, Double-Blind, Placebo Controlled, Parallel Group, Fixed Dose Study of the Efficacy and Tolerability of SB 202026 in Patients Suffering from Dementia of the Probable Alzheimer's Type

An Open Extension Study of the Long Term Safety and Efficacy of SB 202026 in Patients suffering from Dementia of the Probable Alzheimer's Type

Safety and Efficacy of the Seligiline Transdermal Therapeutic System in Patients with Mild to Moderate Alzheimer's Disease

Long-term Safety and Efficacy of Galantamine in the Treatment of Alzheimer's Disease

An Open-Label Study to Evaluate the Safety and Efficacy of 1.5 through 6 mg BID of Exelon (ENA 713) in Patients with Mild to Severe Probable Alzheimer's Disease in the Community Setting

A Randomized, Double-Blind, Placebo-Controlled, Four-Arm Dose-Finding Study Investigating the Efficacy and Safety of Three Doses of Lu 25-109 in Patients with Alzheimer's Disease

An Open-Label Extension Study to Evaluate the Long Term Safety and Tolerability of Lu 25-109 in Patients with Mild to Moderate Alzheimer's Disease

A 24 Week, Multicenter, Randomized, Double-Blind, Placebo- Controlled Evaluation of the Efficacy and Safety of Donepezil in Patients with Dementia Associated with Cerebrovascular Disease

An Open Extension Study of the Long-Term Safety and Efficacy of Galantamine in Patients suffering from Dementia of the Alzheimer's Type

The Efficacy, Safety, and Tolerability of Lazabemide vs Placebo Administered for One Year in Patients with Probable Alzheimer's Disease

A 48 Week Study to Compare the Efficacy and Safety of Propentofylline (HWA 285) with Placebo in Outpatients with Alzheimer's Disease (3018)

A 24 Week Study to Compare the Efficacy and Safety of Propentofylline (HWA 285) with Placebo in Outpatients with Vascular Dementia (3019)

Double-Blind, Placebo-controlled, Safety and Tolerability Study of SR 57746A in Patients with Dementia of the Alzheimer's Type

Randomized, Double-Blind, Placebo-controlled, 12-month Safety and Efficacy Trial of Idebenone (CV-2619) in Patients with Probable Alzheimer's Disease

Randomized, Double-Blind, 12-month Safety and Efficacy Study of Idebenone (CV-2619) or Placebo Added to Treatment with Donepezil in Patients with Probable Alzheimer's Disease

Multi-Center, Randomized, Double-blind, Placebo-controlled Study to Evaluate AIT-082 in Patients with Possible or Probable Alzheimer's Disease of Mild to Moderate Severity

Efficacy and Long-Term Tolerability of Memantine in Patients with Moderately Severe to Severe Alzheimer's Disease

A Prospective, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Effect of Exelon on the Time to Clinical Diagnosis of Probable Alzheimer's Disease in Subjects with Mild Cognitive Impairment

Multicenter, Randomized, Double-blind, Placebo-Control, Parallel-Group, Fixed-Dose Study to Evaluate the Safety and Efficacy of NDD094 in Patients with Mild to Moderate Alzheimer's Disease

Randomized, Double-blind, Placebo-Controlled Study to Determine the Safety and Efficacy of FK960 in Patients with Mild to Moderate Probable Alzheimer's Disease

Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate AIT-082 in Patients with Probable Alzheimer's Disease of Mild to Moderate Severity (90 day Treatment)

Safety and Efficacy of MK-0966 in Delaying the Progression of the Symptoms of Alzheimer's Disease in Patients with Probable AD

Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Subjects with Mild Cognitive Impairment (MCI)

Placebo Controlled Evaluation of Galantamine in the treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled Release Formulation

12-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Three Fixed Doses of Oral CP-457,920 and Donepezil in Outpatients with Alzheimer's Disease

Nursing home-Dementia and Psychoses Studies

Double-Blind Evaluation of the Clinical Usefulness of Low Dose CP-88,059 (Ziprasidone) for the Symptomatic Treatment of Dementia in Institutionalized Patients\

Multicenter, Double-blind Comparison of Efficacy and Safety of Seroquel (Quetiapine), Haloperidol, and Placebo in the Treatment of Elderly Subjects Residing in Nursing Homes or Assisted Care Facilities and Presenting with Alzheimer's Dementia and Psychoses or other Selected Psychoses

Olanzapine in the Management of Behavioral Disturbances and/or Psychosis in Demented Nursing Home Patients
Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Three Fixed Doses of Aripiprazole in the Treatment of Institutionalized Patients with Psychosis Associated with Dementia of the Alzheimer's Type

Schizophrenia-and other Psychoses Studies

A Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Sertindole in Schizophrenic Patients

A Double-Blind Comparison of ICI 204636 (Quetiapine) and Haloperidol in the Prevention of Psychotic Relapse in Outpatients with Schizophrenia

Forty-week, Double-Blind Study Evaluating the Safety and Efficacy of Two Dose Regimens of Oral CP-88,059-1 (Ziprasidone) and Haloperidol in the Maintenance Treatment of Outpatients with Schizophrenia or Schizoaffective Disorder

A Double-Blind, Haloperidol-Referenced Study of the Safety and Efficacy of Two Doses of Sertindole in Schizophrenic Patients

An Open-Label Assessment of the Long-Term Safety of Sertindole In Schizophrenic Patients

Safety and Efficacy of Risperidone 8 mg and 4 mg QD Compared to Placebo in the Treatment of Schizophrenia

A Prospective, Randomized, Multi-Center, Double-Blind, Parallel-Group Study of the Efficacy and Safety of MAR 327 as Compared to Haloperidol and Placebo in Institutionalized Patients with Chronic Schizophrenia

A Fifty Two Week, Double-blind Extension Study Evaluating the Safety and Efficacy of Two Dose Regimens of Ziprasidone and Haloperidol in the Maintenance Treatment of Outpatients with Schizophrenia or Schizoaffective Disorder

A Multicenter, Open Label Trial Evaluating the Safety and Tolerability of Quetiapine (Seroquel) in the Treatment of Elderly Subjects with Selected Idiopathic and Organic Psychoses

A Double-Blind, Randomized, Comparison of the Safety and Efficacy of Sertindole and Risperidone in Treatment Resistant Schizophrenic Patients

A Phase III, Multicenter, Open Label Study Evaluating the Toleration and Safety of 3 Days Treatment with Intramuscular Ziprasidone or Haloperidol Followed by 4 Days of Treatment with Oral Ziprasidone or Haloperidol in Subjects with a Diagnosis of Psychotic Disorder

A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled Study of MDL 100,907 in Schizophrenic and Schizoaffective Patients

A Multicenter, Open-label, Long-term Follow-up, Safety Study of MDL 100,907 in Schizophrenic and Schizoaffective Patients who Participated in the Double-Blind Inpatient Study

U-101387G: Double-blind, Haloperidol-controlled, Safety and Dose-finding Study in the Treatment of Schizophrenia

Double-Blind Evaluation of Risperidone vs Haloperidol on the Long-Term Morbidity of Early Psychotic Patients

A Phase II Multicenter, Double-Blind, Parallel, Randomized Comparison of Oral Fananserin and Placebo Over 28 Days in Patients with Schizophrenia

Double-blind, Placebo-controlled Study of Aripiprazole in the Treatment of Psychosis

A Multicenter, Randomized, Double-Blind, Parallel Group Trial Comparing the Safety and Efficacy of Risperidone and Olanzapine In the Treatment of Psychosis in Patients with Schizophrenia and Schizoaffective Disorder

Multicenter, Placebo and Active Control, Double-Blind, Randomized Study of the Efficacy, Safety, and Pharmacokinetics of M100907 in Schizophrenic and Schizoaffective Patients

Multi-Center, Placebo-controlled Double-Blind Study Comparing the Safety and Efficacy of Ziprasidone and Olanzapine in Subjects with Schizophrenia or Schizoaffective Disorder needing Inpatient Care

Double-Blind, Placebo and Haloperidol-Controlled, Multicenter Study Evaluating the Safety and Efficacy of SR 48692 in Schizophrenic Patients

Double-Blind, Placebo and Haloperidol-Controlled, Multicenter Study Evaluating the Safety and Efficacy of SR 141716 in Schizophrenic Patients

Multi-Center, Open-Label, Long-Term Safety and Efficacy Study of M100907 Tablets Once Daily in Subjects with Schizophrenia or Other Psychotic Disorders

Phase II, Six Week, Double-Blind, Placebo and Olanzapine-Controlled Study Evaluating the Efficacy and Safety of Oral CP-361,428 in Schizophrenia and Schizoaffective Disorder

A Double-Blind, Randomized, Multicenter, Parallel Group Design
Study to Evaluate the Efficacy and Safety of Two Dose Ranges of EMD 128 130 in Comparison with Placebo and Haloperidol in the Treatment of Schizophrenia

A Double-Blind, Five-Armed, fixed-Dose Active and Placebo Controlled Dose-Finding Study with Sublingual ORG 5222 in Subjects with Acute Phase Schizophrenia

Long-Term Extension to Double-Blind, Placebo-Controlled Sublingual ORG 5222 Study in Subjects with Acute Phase Schizophrenia

Multicenter, Randomized, Double-Blind Safety and Tolerability Study of Flexible Doses of Aripiprazole and Olanzapine in the Treatment of Patients with Acute Schizophrenia

Sexual Dysfunction Studies

Pharmacological Treatment of Fluoxetine -Associated Sexual Dysfunction

Multicenter, Double-Blind, Randomized Trial Comparing the Effects of Nefazodone to Sertraline on Sexual Function in Patients with Previously Demonstrated Sexual Dysfunction with Sertraline during Treatment for Major Depression

Double-Blind, Placebo-Controlled Study of Fluparoxan in the Treatment of Secondary (Acquired) Male Erectile Disorder

A Randomized Double-Blind Placebo Controlled Parallel Study to Assess the Efficacy and Safety of Four Oral Dose Levels of RS-15385-197 in Men with Erectile Disorder

A Randomized Pilot Study to Assess the Efficacy and Safety of Two Oral Dose Levels of Delequamine HCL in Men with Erectile Disorder

A Phase III Efficacy and Safety Study of Three Fixed Doses of
Apomorphine SL Tablets Versus Placebo in the Treatment of Male Erectile Dysfunction

A Phase III Long-Term, Open-Label, Flexible Dose, Efficacy and Safety Study of Apomorphine SL Tablets in the Treatment of Male Erectile Dysfunction

A Pilot Observation to Develop Information on Sexual Functioning and Quality of Life in Patients with Obsessive Compulsive Disorder

Phase II, Double-Blind, Placebo-Controlled Flexible Dose Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Viagra for 12 Weeks in Women who are either Post-Menopausal or Post-Hysterectomy with Female Sexual Arousal Disorder

Double-Blind, Placebo-Controlled, Parallel Group Design Study of Lasofoxifene vs. Placebo for the Treatment of Sexual Dysfunction (*Arousal Disorder*) in Postmenopausal Women

Double-Blind, Placebo-Controlled, Parallel Group Design Study of Lasofoxifene vs. Placebo for the Treatment of Sexual Dysfunction (*Hypoactive Desire*) in Postmenopausal Women

Preliminary Efficacy Study in Pre-menopausal Women with Normal or Impaired Sexual Function due to Acquired Arousal and/or Orgasm Disorder Comparing PNU-142774E to Placebo: Double-Blind with 8 week Home Treatment Phase

Obesity Studies

A Placebo-Controlled Study of Dexfenfluramine in the Management of Exogenous Obesity

A Multi-Center, Open-Label, Flexible-Dose Study to Evaluate the Long-Term Effects of Sibutramine Administered for an Additional 18 Months to Relatively Healthy Obese Patients Who Have Participated in Previous Sibutramine Trial

A Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Sustained Release Dexfenfluramine in Obese Outpatients

Echocardiographic Follow-up Study of Subjects who participated in the SR Dexfenfluramine research Protocol

Sleep and Insomnia Studies

Double-blind, Placebo-controlled Study of Estazolam in patients with Insomnia

A Phase III, Double-blind, Comparative and Placebo-Controlled Parallel-Group Safety, Tolerance, and Efficacy Study of Zaleplon compared with Zolpidem or Placebo in Adult Outpatients with Insomnia

Seizure Disorder Studies

The Safety of Intravenous Valproate in Patients with Seizure Disorder

Parkinson's Disease Studies

Efficacy and Safety of Open-Label Quetiapine in the Management of Psychosis in Patients with Parkinson's Disease

Phase III, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Study of the Effect of Riluzole for Two Years on the Progression of Parkinson's Disease

Migraine Studies

A Long-Term, Open Label, Phase III Trial to Evaluate theEfficacy, Safety and Tolerability of Alniditan in the Acute Treatment of Migraine

Efficacy and Safety of Alniditan 1.4 or 1.8 mg SC vs Sumatriptan (6 mg SC) in the Acute Treatment of Migraine: A Randomized, Double-Blind Placebo-Controlled Single-Dose Trial

Multicenter, Double-Blind, Randomized Comparison of Zolmitriptan (ZOMIG) and Sumatriptan in the Acute Treatment of Multiple Migraine Headaches

A Double-Blind, Parallel, Placebo-Controlled, Single-Dose Study of the Activity of Four Dose Levels of Ganaxolone for the Treatment of Migraine Headaches With or Without an Aura in Females

Single-Dose, Randomized, Double-blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Two Doses of Ibuprofen for the Treatment of Migraine Headache Pain

Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Acetoaminophen 1000 mg for the Treatment of Migraine Headache Pain

Single-Dose, Double-Blind, Safety and Efficacy Study of MT100, Metoclopramide Hydrochloride and Naproxen Sodium in subjects with Acute Migraine Attacks

Double-Blind, Placebo-Controlled Trial of Zolmitriptan for the Acute Treatment of Migraine Headaches in Adolescent Patients

Other Medical Studies

A 26-Week, Double-Blind, Parallel, Multicenter, Multi-Country Comparison of SKB 108566 and Enalapril on Cough and Blood Pressure with Essential Hypertension

A Long-term (One-Year) Open-label, Multicenter Extension of Twice Daily Oral SKB 108566 in Patients with Essential Hypertension

Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Effectiveness of a Single IV Dose, Rising IV Dose of SB 210396 in Patients with Stable Moderate to Severe Asthma

A Double-Blind, Randomized, Parallel Group, Multicenter Comparison of the Efficacy and Safety of Mycophenolate Mofetil po and Placebo in Patients with Active Rheumatoid Arthritis Who are Candidates for Immunosuppressive Therapy of RA

Clinical Protocol for a Double-blind, Placebo Controlled, Randomized Comparison Study of the Efficacy and Safety of SC-58635 bid and Naproxen bid in Treating the Signs and Symptoms of Osteoarthritis of the Hip

A Randomized, Double-Blind, Placebo Controlled Six Month Safety and Efficacy Trial of Pioglitazone in Type II Diabetes Mellitus Patients

Randomized, Double-blind, Placebo-controlled Two year Study of The Efficacy and Safety of GI198745 in the Treatment of Benign Prostatic Hyperplasia

A Clinical Protocol to Evaluate the Long-Term Safety of Meloxicam in Treating the Signs and Symptoms of Osteoarthritis and Rheumatoid Arthritis

A Randomized, Comparative, Multicenter, Safety and Contraceptive Efficacy Study of Two Cyclophasic Norgestimate/Ethinyl Estradiol Regimens, and One Triphasic Norgestimate/Ethinyl Estradiol Regimen and Loestrin Fe 1/120

A Multicenter, Double-Blind, Controlled, Randomized Study to Determine Efficacy in the Relief of Hot Flashes in Women Receiving Transdermal Estradiol Compared to Oral Conjugated Estrogens

Publications

1. Targum, S.D., Wright, N.H., "Association of the Intrauterine Device and Pelvic Inflammatory Disease: A Retrospective Pilot Study", Am J Epidemiol 100:262-271, 1974

2. Gershon, E.S., Targum, S.D., Kessler, L.R., Mazure, C.M., Bunney, Jr., W.E., "Genetic Studies and Biological Strategies in the Affective Disorders", Prog Med Genet, II:101-164, 1977

3. Gershon, E.S., Targum, S.D., Leckman, J.F., "Platelet Monamine Oxidase (MAO) Activity and Genetic Vulnerability to Bipolar (BP) Affective Illness", Psychopharm Bull, 15:27-30, 1979

4. Reus, V.I., Targum, S.D., Weingartner, H., Post, R.M., "Effect of Lithium Carbonate on Memory Processes of Bipolar Affectively Ill Patients", Psychopharm 63:39-42, 1979

5. Targum, S.D., Gershon, E.S., VanEerdewegh, M., Rogentine, N., "The Human Leukocyte Antigen (HLA) System and Bipolar Affective Illness", Biol Psychiat, 14:615-633, 1979

6. Gershon, E.S., Targum, S.D., Matthysse, S., Bunney, Jr., W.E., "Color Blindness Not Closely Linked to Bipolar Illness, A Report of a New Pedigree Series" Arch Gen Psychiat, 36:1423-1430, 1979

7. Lechman, J.F., Gershon, E.S., McGinniss, M.H. Targum, S.D., Dibble, E.D., "New Data Do Not Suggest Linkage Between the Xg Blood Group and Bipolar Illness", Arch Gen Psychiat, 36:1435-1441, 1979

8. Targum, S.D., Davenport, Y.B., Webster, M.J., "Postpartum Mania in Bipolar Manic-Depressive Patients Withdraw from Lithium Carbonate", J. Nerv Ment Dis, 1976:572-574, 1987

9. Targum, S.D., Gershon, E.S., Shen, R., Abell, C.W., "Screening for PKU Heterozygosity in Bipolar Affectively Ill Patients", Biol Psychiat, 14:651-655, 1979

10. Sparkes, R.S., Targum, S.D., Gershon, E., Sensabaugh, G.F., Sparkes, M.C., Crist, M., "Evidence for a Null Allele at the Esterase D EC 3.1.1.1.) Locus", Hum Genet, 46:319-323, 1979

11. Targum, S.D., "Dealing with Psychosis During Pregnancy", Am Pharm, 19:482-485, 1979

12. Targum, S.D., Weiss, J.O., "A Genetic Disease in the Family", Psychiat Opin, 17:23-25, 1980

13. Targum, S.D., "Family Tree Gives clues to Treating Psychosis", Am Pharm, 11:44-47, 1980

14. Targum, S.D., Gershon, E.S., "Genetic Counseling for Affective Illness", in Mania: an evolving concept, ed by Belmaker, R., Van Praage, H.M., Spectrum Publications, New York: 119-126, 1980

15. Targum, S.D., "Psychotherapeutic Consideration in Genetic Counseling", Am J Med Genetics, 8:281-289, 1981

16. Targum, S.D., "Psychiatric Genetic Counseling", J Psychiat Treat and Eval, 3:263-269, 1981

17. Targum, S.D., Dibble, E.D., Davenport, Y.B., Gershon, E.S., "Family Attitudes Questionnaire: Patients' and Spouses' View Bipolar Illness, Arch Gen Psychiat, 38:562-568, 1981

18. Frank, E., Targum, S.D., Gershon, E.S., Anderson, C., Stewart, B.D., Davenport, Y., Ketchum, K.L., Kupfer, D.J., "A Comparison of Non-Patient and Bipolar Patient-Well Spouse Couples", Am J Psychiat, 138:764-768, 1981

19. Targum, S.D., Chastek, C.T., Sullivan, A.C., "Dexamethasone Suppression Test in Prepubertal Conduct Disorders", Psychiat Res, 4:107-108, 1981

20. Targum, S.D., Gershon, E.S., "Pregnancy, Genetic Counseling, and the Major Psychiatric Disorders", in Genetic Diseases and Pregnancy, ed Schulman, J., Simpson, J., Academic Press, New York, 413-438, 1981

21. Sullivan A.C., Targum, S.D., Advani, M., "Variables Related to the Outcome of Treatment for Inpatient Alcoholics", Alcoh Health and Res Wld, 6:58-60, 1981

22. Targum, S.D., "The Adaptation to Genetic Renal Disease: Polycycstic Kidneys" Controversies in Nephrology, ed Schreiner, G.E., Winchester, J.F., Georgetown Univ, 3:175-184, 1981

23. Targum S.D., Schulz, S.C., "Clinical Applications of Psychiatric Genetics", Am J Orthopsychiat, 52:45-57, 1982

24. Targum, S.D., Capodanno, A.E., Hoffman, H.A., Foudraine, C., "An Intervention to Reduce the Rate of Hospital Discharges Against Medical Advice" Am J. Psychiat, 139:657-659, 1982

25. Targum, S.D., Sullivan, A.C., Byrnes, S.M., "Compensatory Pituitary-Thyroid Mechanisms in Major Depressive Disorder", Psychiat Res, 6:85-99, 1982

26. Targum, S.D., Byrnes, S.M., Sullivan, A.C., "Subtypes of Unipolar Depression Distinguished by the Dexamethasone Suppression Test", J Affect Dis, 4:21-27, 1982

27. Targum, S.D., Byrnes, S.M., Sullivan, A.C., "The TRH Test in Subtypes of Unipolar Depression", J Affect Dis, 4:29-34, 1982

28. Targum S.D., Sullivan A.C., Byrnes, S.M., "Neuroendocrine Interrelationships in Major Depressive Disorder", Am J Psychiat, 139:282-286, 1982

29. Weinberger, D.R., DeLisi, L.E., Perman, G.P., Targum, S., Wyatt, R.J., "Computed Tomography in Schizophreniform Disorder and Other Acute Psychiatric Disorders", Arch Gen Psychiat, 39:778-793, 1982

30. Targum, S.D., Capodanno, A.E., Unger, S., "The Post Hospital Adjustment of Psychiatric Patients, A Six-Month Follow-Up Survey", The Psychiat Hosp, 13:35-39, 1982

31. Schulz, P.M. Schulz, S.C., Dibble, E., Targum, S.D., van Kammen, D.P., Gershon, E.S., "Patient and Family Attitudes About Schizophrenia: Implications for Genetic Counseling", Schizo Bull, 8:504-513, 1982

32. Targum, S.D., Wheadon, D.E., Chastek, C.T., McCabe, W.J., Advani, M.T., "Dysregulation of Hypothalamic-Pituitary-Adrenal Axis Function in Depressed Alcoholic Patients", J Affect Dis, 4:347-353, 1982

33. Gershon, E.S., Hamovit, J., Guroff, J.J., Dibble, E., Leckman, J., Sceery, W., Targum S.D., Nurnberger, J.I., Goldin, L.R., "A Family Study of Schizoaffective, Bipolar I, Bipolar II, Unipolar, and Normal Control Probands", Arch Gen Psychiat, 39:1157-1167, 1982

34. Targum, S.D., "The Applications of Serial Neuroendocrine Challenge Studies in the Management of Depressive Disorder", Biol Psychiat, 18:3-19, 1983

35. Targum S.D., "Neuroendocrine Dysfunction in Schizophreniform Disorder: Correlation with Six Month Outcome", Am J Psychiat, 140:309-313, 1983

36. Targum, S.D., Rosen, L.N., DeLisi, L.E., Weinberger, D.R., Citrin, C.M., "Cerebral Ventricular Size in Major Depressive Disorder: Association with Delusional Symptoms, Biol Psychiat, 18:329-336, 1983

37. Targum, S.D., Capodanno, A.E., "The Dexamethasone Suppression Test in Adolescent Psychiatric Patients, Am J Psychiat, 140:589-591, 1983

38. Targum, S.D., Rose, L.N., Citrin, C.M., "Delusional Symptoms Associated with Enlarged Cerebral Ventricles in Depressed Patients", South Med J, 76:985-987, 1983

39. Siever, L.J., Uhde, T.W., Jimerson, D.C., Kafka, M.S., Lake, C.R., Targum, S., Murphy, D.L., "Clinical Studies of Monoamine Receptors in the Affective Disorders and Receptor Changes with Antidepressant Treatment", Prog Neuro-Psychopharm & Biol Psychiat, 9:249-261, 1983

40. Targum, S.D., "Neuroendocrine Challenge Studies in Clinical Psychiatry", Psychiat Ann, 13:385-395, 1983

41. Targum, S.D., Rosen, L., Capodanno, A.E., "The Dexamethasone Suppression Test in Suicidal Unipolar Depression", Am J Psychiat, 140:877-879, 1983

42. Goldin, L.R., Gershon, E.S., Targum, S.D., Sparkes, R.S., McGinnis, J., "Segregation and Linkage Analysis in Families of Patients with Bipolar, Unipolar and Schizoaffective Mood Disorders", Am J Human Genet, 35:274-287, 1983

43. Capodanno, A.E., Targum, S.D., "Assessment of Suicide Risk: Some Limitations in the Prediction of Infrequent Events", J Psychosoc Nurs, 21:11-14, 1983

44. DeLisi, L.E., Schwartz, C.C., Targum, S.D., Byrnes, S.M., Cannon-Spoor, E., Weinberger, D.R., Wyatt, R.J., "Ventricular Brain Enlargement and Outcome of Acute Schizophreniform Disorder", Psychiat Res, 9:169-171, 1983

45. Targum, S.D., "Reported Weight Loss and the Dexamethasone Suppression Test", Psychiat Res, 9:173-174, 1983

46. Siever, L.J., Kaye, W.H., Jimerson, D.C., Lake, C.R., Kafka, M., Targum, S.D., Murphy, D.L., "Abnormalities in the Primary Affective Disorders Compared to Other Tricyclic-Responsive Disorders", Psychopharm Bull, 19:435-436, 1983

47. DeLisi, L.E., Karoum, F., Targum, S., Brynes, S., Wyatt, R.J., "The Determination of Urinary 3-Methoxy-4-Hydroxyphenylglycol Excretion in Acute Schizophreniform and Depressed Patients", Biol Psychiat, 18:1189-1196, 1983

48. Targum S.D., "Psychobiologic Evaluation of Psychiatric Disorders", in Textbook of Contemporary Psychiatry;, ed Dunn, C., Gibson, The Collamore Press, Lexington, Mass: 27-41, 1984

49. Kessler, K., Targum, S.D., "Psychopharmacologic Treatment", in Textbook of Contemporary Psychiatry, ed Dunn, C., Gibson, The Collamore Press, Lexington, Mass: 281-320, 1984

50. Capodanno, A.E., Fram, D.H., Holden, R., Targum, S.D., "The Out-Patient Treatment of Heroin Addicts with Methadone: A Two to Five Year Follow-up Study", Psychiat Hosp, 15:25-30, 1984

51. Targum, S.D., Kessler, K., Waletsky, J., Sullivan, A., "Upgrading Psychopharmacology in a Private Psychiatric Hospital", Hosp Comm Psychiat, 35:385-387, 1984

52. Targum, S.D., "Persistent Neuoendocrine Dysregulation and Major Depressive Disorder: A Marker for Early Relapse", Biol Psychiat, 19:305-318, 1984

53. Targum, S.D., Capodanno, A.E., Unger, S., Advani, M., "Abnormal Dexamethasone Tests in Withdrawing Alcoholic Patients", Biol Psychiat, 19:401-405, 1984

54. Targum, S.D., "Psychiatric Genetics: Implications for Counseling Patients and Their Families", in Genetic Disorders and Birth Defects in Families and Society: Toward Interdisciplinary Understanding, ed Weiss, J., Bernhardt, B., Paul, N., March of Dimes Defects Foundation, White Plains, NY, 50-55, 1984

55. Targum S.D., Greenberg, R.D., Harmon, R.L., Kessler, K., Salerian, A.J., Fram, D.H., "The TRH Test and Thyroid Hormone in Refractory Depression", Am J Psychiat, 141-463, 1984

56. DeLisi, L.E., Murphy, D.L., Karoum, F., Mueller, E., Targum, S.D., Wyatt, R.J., "Phenylethylamine Excretion in Depression", Psychiat Res, 13:193-201, 1984

57. Walsh, J.K., Targum, S.D., Pegram, V., Allen, R.P., Fillingim, J.M., Parwatikar S., Schweitzer, P.K., "A Multi-Centered Clinical Investigation of Estazolam: Short Term Efficacy", Curr Therap Res, 36:866-874, 1984

58. Targum S.D., Greenberg, R., Harmon R., Kessler, K., Salerian, A., Fram, D. "Thyroid Hormone and the TRH Stimulation Test in Refractory Depression", J Clin Psychiat, 45:345-346, 1984

59. Targum, S.D., "Serial Dexamethasone Tests and the Prediction of Relapse in Depressive Disorder", South Med J, 77:1402-1405, 1984

60. Targum S.D., White, P., Collins-Rothe, H., Sullivan P., "Serum Aldosterone Following Dexamethasone in Depressed Patients", Psychoneuroend, 9:305-309, 1984

61. DeLisi, L.E., King, A.C., Targum, S.D., "Serum Immunoglobulin Concentrations in Patients Admitted to an Acute Psychiatric In-Patient Service", Brit J Psychiat, 145:661-666, 1984

62. Siever, L.J., Kafka, M.S., Targum, S.D., Lake, C.R., "Platelet alpha-Adrenergic Binding and Biochemical Responsiveness in Depressed Patients and Controls", Psychiat Res, 11:287-302, 1984

63. Targum S.D., "The Relevance of the Dexamethasone Suppression Test to the Prediction of Treatment Response", Proc NIMH Workshop: Clinical Utility of the Dexamethasone Test, DHHS Publ. (ADM) 85-1313:35-39, 1985

64. Silberman, E.K., Weingartner, H., Targum S.D., Byrnes, S., "Cognitive Functioning in Biological Sub-types of Depression", Biol Psychiat, 20:654-661, 1985

65. Siever, L.J., Uhde, T.W., Insel, T.R., Kay, W.H., Jimerson, D.C., Lake, C.R., Kafka, M., Targum, S.D., Murphy, D.L., "Biological Alternations in the Primary Affective Disorders and Other Tricyclic-Responsive Disorders", Prog Neuropsychopharm & Biol Psychiat, 9:15-24, 1984

66. Targum, S.D., Docherty, J.P., "The Future of Research in Private Psychiatric Hospitals", The Psychiat Hosp, 16:115-119, 1985

67. Kafka, M.S., Siever, L.J., Nurnberger, J.I., Uhde, T.W., Targum, S.D., Coopers D.M.J., van Kammen, D.P., Tokola, N.S., "Platelet Alpha-Adrenergic Receptor Function in Affective Disorders and Schizophrenia", Psychopharm Bull, 21:599-602, 1985

68. Capodanno, A.E., Targum, S.D., Unger, S., "Dimensions of Social Adjustment Following Psychiatric Hospitalization: A 6 Month Follow-up Study", The Psychiat Hosp, 17:27-32, 1986

69. Targum, S.D., "Research on the Pharmacology and Psychobiology of Depressive Disorders", Current Research in Private Psychiatric Hospitals, National Association of Private Psychiatric Hospitals, Washington, D.C., 1-12, 1987

70. Targum, S.D., "Genetic issues in treatment", in Affective Disorders and the Family, ed Clarkin, J.F., Haas, G.L., Glick, I.D., Guilford Press, New York, 196-212, 1988

71. Davis, K.L., Davidson, M., Yang, R., Davis, B.M., Siever, L.J., Mohs, R.C., Ryan, T., Coccaro, E., Bierer, L., Targum S.D., "CSF Somatostatin in Alzheimer's Disease, Depressed Patients and Control Subjects", Biol Psychiat, 24:710-712, 1988

72. Targum, S.D., Marshall, L.E., "Fenfluramine Provocation of Anxiety in Patients with Panic Disorder", Psychiat Res, 28:295-306, 1989

73. Targum, S.D., Marshall, L.E., Fischman, P., Martin, D., "Lymphocyte Subpopulations in Depressed Elderly Women", Biol Psychiat, 26:581-589, 1989

74. Targum, S.D., Marshall, L.E., Magac-Harris, K., Martin, D., "TRH Tests in a Healthy Elderly Population: Demonstration of Gender Differences", J Am Geriat Soc, 37:533-536, 1989

75. Targum, S.D., Clarkson, L.L., Magac-Harris, K., Marshall, L.E., Skwerer, R.G., "Measurement of Cortisol and Lymphocyte Subpopulations in Depressed and Conduct Disordered Adolescents", J Affect Disord, 18:91-96, 1990

76. Rosen, L.N., Targum, S.D., Terman, M., Bryant, M.J., Hoffman, H., Kasper, S.F., Hamovit, J.R., Docherty, J.P., Welch, B., Rosenthal, N.E., "Prevalence of Seasonal Affective Disorder at Four Latitudes", Psychiat Res, 31:131-144, 1990

77. Targum, S.D., "Differential Responses to Anxiogenic Challenge Studies in Patients with Major Depressive Disorder and Panic Disorder", Biol Psychiat, 28:21-34, 1990

78. Targum, S.D., "Mechanisms of Anxiogenic Vulnerability in Panic Disorder", Psychiat Res, 31:215-216, 1990

79. Targum S.D., "Panic Attack Frequency and Vulnerability to Anxiogenic Challenge Studies", Psychiat Res, 36:75-83, 1991

80. Targum S.D., Caputo, K.P., Ball, S.K., "Menstrual Cycle Distribution and Psychiatric Admissions", J Affect Disor, 22:49-53, 1991

81. Carson, S.L., Targum S.D., "Panic Attacks After Cessation of Phenoxybenzamine: A Case Report", Ann of Clin Psychiat, 3:325-327,1991

82. Targum, S.D., "Cortisol Response During Different Anxiogenic Challenges in Panic Disorder Patients", Psychoneurendocinol, 17:1-7, 1992

83. Targum S.D., Marshall, L.E., Fischman, P., "Variability of TRH Test Responses in Depressed and Normal Elderly Subjects", Biol Psychiat, 31:787-793, 1992

84. Targum, S.D., "TRH Test in Depression and Use of an Ultrasensitive TSH Assay: ", Biol Psychiat, 34:122-124, 1993

85. van Kammen, D.P., McEvoy, J.P., Targum S.D., Kardatzke, D., Sebree, T.B., and the Sertindole Group, "A Randomized, Controlled, Dose-Ranging Trial of Sertindole in Patients with Schizophrenia", Psychopharm, 124:168-175, 1996

86. Feighner, J., Targum, S.D., Bennett, M.E., Roberts, D.L., Kensler, T.T., D'Amico, M.F., Hardy, S.A., "A Double-Blind, Placebo-Controlled Trial of Nefazodone in the Treatment of Patients Hospitalized for Major Depression", J Clin Psychiat., 59: 246-253, 1998.

87. Targum, S.D., Abbott, J.L., "Psychoses in the Elderly: A Spectrum of Disorders," J. Clinical Psychiat., 60 (suppl 8): 4-10, 1999.

88. Thal, L.J., Ferguson, J.M., Mintzer, J., Raskin, A., Targum, S.D., "A 24-Week Randomized Trial of Controlled-release Physostigmine in Alzheimer's Disease," Neurology, 52: 1146-1152, 1999.

89. Targum, S.D., Abbott, J.L., "Efficacy of Quetiapine in Parkinson's Patients with Psychosis", J Clin Psychopharm., 20: 54-60, 2000.

90. Michelson, D., Bancroft, J., Targum, S., Kim., Y., Tepner, R., "Female Sexual Dysfunction Associated with Antidepressant Administration: A Randomized, Placebo-Controlled Study of Pharmacologic Intervention," Am J Psychiat., 157: 239-243, 2000.

91. Targum, S.D. "SSRI's and Sexual Dysfunction," Drug Benefit Trends, 12 (9): 3-12, 2000.

92. Targum, S.D. "New Treatments for Alzheimer's and Parkinson's Disease," Contemporary Long Term Care, 24 (1): 39-40, 2001

93. Targum, S.D. "Treating Psychotic Symptoms in Elderly Patients," Primary Care Companion, J Clin Psychiat., 3: 156-163, 2001.

94. Feltner, D.E., Crockatt, J.G., Dubovsky S.J., Cohn C.K., Shrivastava, R.K., Targum, S.D., Liu-Dumaw, M., Carter C.M., Pande, A.C. "A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study of Pregabalin in Patients with Generalized Anxiety Disorder," J Clin Psychopharm., 23 (3) 240-249, 2003.

95. Mintzer J., Targum, S.D. "Psychosis in Elderly Patients: Classification and Pharmacotherapy," J Geriatr Psychiatry Neurol, 16: 199-206, 2003.

96. Nasrallah, H.A., Targum, S.D., Tandon, R., McCombs, J.S., Ross, R., "Defining and Measuring Clinical Effectiveness in the Treatment of Schizophrenia," Psychiatric Services 56: 273-282, 2005.

97. Targum, S.D., "Evaluating Rater Competency for CNS Clinical Trials," J. Clin Psychopharm., 26 (3) 308-310, 2006.

98. Tandon, R., Targum, S.D. Nasrallah, H.A., Ross, R., "Strategies for Maximizing Clinical Effectiveness in the Treatment of Schizophrenia," J Psychiatric Practice, 12: 348-363, 2006.

99. Mackin, P., Targum, S.D., Kalali, A., Rom, D., Young, A.H., "Culture and Assessment of Manic Symptoms," Brit. J. Psychiat., 12: 379-380, 2006.

100. Busner J., Targum, S.D., "The Clinical Global Impressions Scale: Applying a Research Tool in Clinical Practice," Psychiatry, 4 (7): 29-37, 2007.

101. Targum, S.D., Busner, J., Miller, D., Braxton, E., "Rater scoring variability in the serial assessment of anxiety symptoms," J Clin. Psychopharm., 28 (1): 118-119, 2008.

102. Targum, S.D., "Biomarkers for the Identification and Treatment of Dementia," Psychiatry, 5 (2) 51-56, 2008.

103. Targum, S.D., Pollack, M.H., Fava, M., "Re-defining Affective disorders: Relevance for Drug Development," CNS Neuroscience and Therapeutics, 14: 2-9, 2008.

104. Targum, S.D., Busner J., Dunn, J., "Confounding Influence of Extraneous Symptoms on CGI Ratings for Depression," J Clin Psychopharm., 28 (5): 587-589, 2008.

105. Lannfelt L., Blennow K., Zetterberg H., Batsman S., Ames D., Harrison J., Masters CL., Targum S., Bush AI., Murdoch R., Wilson J., Ritchie CW., Targeting Aβ as a modifying therapy of Alzheimer's disease: safety, efficacy and biomarker findings of a Phase IIa Randomised, Double-Blind Placebo-Controlled trial of PBT2," Lancet Neurology 7: 779-786, 2008.

106. Targum, S.D., Busner, J., Young, A.H. "Targeted Scoring Criteria Reduces Variance in Global Impressions," Human Psychopharmacology: Clinical and Experimental, 23: 628-633, 2008.

107. Busner, J., Targum, S.D., Miller, D. "The Clinical Global Impressions Scale: Errors in Understanding and Use," Comprehensive Psychiat., 50 (3): 257-262, 2009.

108. Targum, S.D. and Fava, M. "The relevance of anxious depression as a distinct entity for psychopharmacology and drug development," U.S. Psychiatry, 2: 29-31, 2009.

109. Ereshefsky, L., Targum, S., Toumi, M. "Sertindole is associated with reduced health care use by patients with schizophrenia," submitted to Schizophrenia Bulletin, June, 2009.

110. Chandler, G.M. Iosifescu, D., Pollack, M., Targum, S.D., Fava, M., "Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ)," CNS Neuroscience and Therapeutics, in press.

Book:

Targum, S.D., "Psychiatric Skeletons: Tracing the Legacy of Mental Illness in the Family", New York, Villard Press, 1989

Selected Recent Presentations:

Busner J., Targum, S.D., "Effect of adverse events on multinational clinical global impressions (CGI) ratings in schizophrenia," 14th Winter Workshop on Schizophrenia and Bipolar Disorders, Montreux, Switzerland, February 3-8, 2008.

Targum, S.D., Joan Busner J., Judith Dunn, J., "CGI Scoring Ambiguity can Adversely Affect Clinical Trials," 48th Annual NCDEU meeting, Phoenix, AZ, May 28, 2008.

Targum, S.D. Pollack, M., Fava M., "Re-defining Mood Disorders for Clinical Drug Development," 48th Annual NCDEU meeting, Phoenix, AZ, May 28, 2008.

Targum, S.D., "Approaches to Improve Outcomes in CNS Clinical Trials," 21st European Congress of Neuropsychopharmacology (ECNP), Barcelona, Spain, September 2, 2008.

Chandler, G.M., Targum S.D., Pollack, M., Mischoulon, D. Iosifescu, D., Perlis, R.H., Witte, J., Fava, M., "Validation of Patients for a CNS Trial of Major Depressive Disorder," 49th Annual NCDEU meeting, Hollywood, FL, June 30, 2009.

Targum, S.D., Bleicher L.S., Nierenberg A.A., Barlow C., Robinson J., Wedel P. "Evaluation of Centralized Ratings in a Clinical trial of Major Depressive Disorder," 163rd Annual meeting of the American Psychiatric Association, New Orleans, LA, May 24, 2010.

Targum, S.D., "The Enigma of Ratings Accuracy in CNS Trials" 50th Annual NCDEU meeting, Boca Raton, FL, June 14, 2010.

Updated June 25, 2010